Once rabies virus invades the central nervous system (CNS), it produces an almost invariably fatal disease (19) . Strenuous treatment procedures including intensive care (7, 20) have been instituted in people with symptoms of the disease. In one case these efforts actually resulted in the patient's recovery (10) , and in that case a high level of neutralizing antibody was found in the cerebrospinal fluid (CSF), similar to the levels seen in the other human cases in which intensive care resulted in prolonged survival periods (7) . Moreover, in animal experiments, only those dogs recovering from CNS disease have had antibody in the CSF (3, 5) , suggesting that there may be a relationship between those antibodies and recovery. It occurred to us that the production of CSF antibody without accompanying disease might be achieved by injecting high-titered attenuated virus into the CSF, and that the resultant antibody might affect recovery from rabies. The experiments described here were designed to answer those questions.
MATERIALS AND METHODS
Animals. The animals used were purebred 2-yearold beagles, juvenile rhesus monkeys (Macaca mulatta), and yearling black Angus steers. None had been vaccinated against rabies, and no animal had neutralizing antibody (17) to the virus. The white Swiss mice used for virus titrations were of the ICR strain, either suckling (1-to 3-day-old) or weanling (3-week-old); those used for vaccine potency testing were 4 weeks old.
Vaccines. The attenuated vaccine administered to dogs was ERA (1; M. K. Abelseth, Ph.D. thesis, Univ. of Minnesota, Minneapolis, 1966) grown on BHK cells (13) with a mouse intracerebral mean lethal dose (MICLD50) titer of 10'6/0.03 ml. This vaccine was also administered to dogs after being inactivated with a 1:4,000 dilution of beta-propiolactone. Three vaccines were administered to rhesus monkeys: a highly potent (and inactivated) ERA-BHK vaccine concentrated by the method of Schneider (16) healthy, yet CSF antibody developed by the 4th day after inoculation ( Table 1 ). The brain suspensions of those that received the live vaccine, however, had neutralizing antibody, whereas those that received the inactivated one did not.
Since intrathecal administration of vaccine had resulted in the production of CSF antibody without causing illness, we decided that we should then try to save animals sick with rabies by administering attenuated vaccine. The first such attempt was made in 12 challenged dogs, and we were primarily interested in determining the appropriate anesthetic agent and precise inoculation site. We vaccinated these dogs (experiment 1) when the first signs of rabies appeared. Three dogs (no. 87, 92, and 84) died of trauma while being inoculated, and six others died soon after being treated. The remaining three (no. 80, 44, and 8), however, had markedly prolonged morbidity periods and recovered from the disease (Fig. 1 ). These three, while still Moreover, tests were then done to show that those animals that might sicken and recover actually had been rabid. CSF was tested for rabies when it was drawn at the time of intrathecal vaccination, salivary swabs were taken (12) , and skin biopsies (18) were excised at three sites for fluorescent antibody examination.
None of the dogs treated 1 week after challenge died (Fig. 2) . Four control animals died with incubation periods that varied from 12 to 16 days and with morbidity periods of 1 to 3 days. Two of the four symptomatic dogs that were vaccinated intrathecally had markedly longer morbidity periods than the control animals (8 and 12 versus 1 to 4). The signs in these paralyzed animals were again notably different from the control animals. Virus was isolated from the saliva of the dog that survived for 12 days on two occasions, the 1st and 7th days of illness. The isolation attempts on the other dogs were negative.
The next trials were with rhesus monkeys. Because of the known susceptibility of that species to intracerebral administration of HEP (11), the most attenuated live rabies vaccine available to us, we began working with the concentrated inactivated vaccine we had prepared. Four monkeys were inoculated with 1 ml each of this material, two intrathecally and two intravenously via the femoral vein. Serum samples and CSF were drawn at vaccination, at 3, 6, 24, and 48 h, and then at 3, 4, and 7 days; the first five samples were tested for interferon levels, the last three for neutralizing antibody determination. Interferon appeared in both serum and CSF of all four monkeys, with higher CSF levels in the two monkeys given the vaccine intrathecally (Table 2 ). Neutralizing antibody appeared earlier in the sera of the three surviving monkeys than in CSF, and reached higher levels. When the last two monkeys were killed and examined 1 year after vaccination, both had neutralizing antibody in their sera, but only the one originally given vaccine intrathecally had antibody in the CSF and (a low level) in brain suspension.
With the high CSF interferon and neutralizing antibody levels in mind, we planned an experiment evaluating the efficacy of intrathecal administration of the potent inactivated vaccine in rabid monkeys. Ten rhesus monkeys were inoculated in the neck muscles with 1. (Table 3) . We next turned to the intrathecal administration of attenuated ERA vaccine in monkeys. Every dilution of vaccine inoculated from the very concentrated to the very dilute produced rabies in the monkeys, in spite of the appreciable interferon and neutralizing antibody levels in the CSF long before the animals sickened or died (Table 4) . Another attenuated vaccine, HEP, was also injected and again proved lethal (11) with, however, surprisingly long incubation periods in the animals given the higher dilutions of vaccine. Most of the animals that died after receiving either ERA or HEP had neutralizing antibody in the brain.
The last species inoculated was the bovine (Table 5) ; their susceptibility appeared to be similar to that of dogs, with no animals dying after receiving ERA-BHK (MICLD,60 of 106 6/0.03 ml) and subsequent development of antibodies in both CSF and serum. Both the cisternal and lumbar routes were used in the experiment since it was not known which would be the easier route of administration.
DISCUSSION
Recovery from rabies in the CNS has only rarely been noted, but on those few occasions high levels of neutralizing antibodies were pres- ent in the CSF (3, 5, 10) . This suggests that reticuloendothelial cells not usually reached were stimulated by the virus. Arko et al. (3) showed that neutralizing antibody does not "cross over" to the CSF, even when present at very high levels in the face of a fatal encephalitis, adding further weight to this initial evidence. The relationship between cerebral resistance to virus infection and the presence of neutralizing antibody in the CSF has long been known; Morgan et al. (14) reported that rabbits vaccinated subcutaneously with Eastern equine encephalomyelitis virus resisted intracerebral challenge only when spinal fluid antibody was induced, the resistance being "a true immunity, dependent on strain-specific neutralizing antibodies." They also stated that "another type of resistance, not strain specific, and not de- Our results indicate that although CSF antibodies (and interferon) may be elicited by both attenuated and inactivated vaccines, recovery from CNS infection and prolonged morbidity periods appear to be related to additional factors, since highly concentrated inactivated vaccine (when given at the first signs of the disease) not only failed to prolong the morbidity period but markedly shortened it.
In contradistinction to this, attenuated vaccine tended to prolong the morbidity period and to radically affect the symptomatology of some sick animals. We found that the intrathecal inoculation of the attenuated vaccine in dogs and rhesus monkeys resulted in the development of cerebral antibodies (i.e., in suspensions of brain material), whereas the inoculation of the inactivated vaccine did not. We thus conclude that the stimulation of brain immunocompetent cells, interference, or other factors dependent on replication of attenuated virus were the critical factors in the prolonged illness periods noted and occasional canine recovery. Some dogs recovered even without the intensive care essential for "treatment" of rabies in man (monitoring of blood gases, administration of anticonvulsant drugs, reduction of increased CSF pressure and tracheostomy), and if those procedures had been instituted in addition to the intrathecal vaccination, even more animals might have recovered.
Perhaps the immune response to the live rabies vaccine is similar to the local antibody response found in the CNS of rhesus monkeys given intrathalamic inoculations of the Mahoney and Sabin strains of poliovirus (15) ; no local (CNS) antibody was produced after similar injection of inactivated vaccine, and it was suggested that the CNS, when stimulated locally by a potent, replicating vaccine, elicits a local antibody response. We were unfortunately not able to test the possible saving effect of such a local antibody response in monkeys given attenuated rabies vaccines intrathecally, since animals inoculated with those vaccines died of vaccine-induced rabies. Further studies in subhuman primates must thus await the development of a more highly attenuated virus. The ultimate aim, of course, would be to develop procedures permitting the same general conditions of disease alleviation in man.
The results in cattle suggest that intrathecal vaccination experiments with ERA-BHK should be carried out in an attempt to alter the disease course in cattle, especially in those Latin American areas where bovine rabies is a definite problem (2) .
